Profund Advisors LLC Sells 20,902 Shares of Roivant Sciences Ltd. $ROIV

Profund Advisors LLC lessened its stake in Roivant Sciences Ltd. (NASDAQ:ROIV) by 16.4% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 106,639 shares of the company’s stock after selling 20,902 shares during the quarter. Profund Advisors LLC’s holdings in Roivant Sciences were worth $1,613,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in ROIV. Candriam S.C.A. grew its position in shares of Roivant Sciences by 43.5% during the 3rd quarter. Candriam S.C.A. now owns 2,157,995 shares of the company’s stock worth $32,650,000 after buying an additional 654,001 shares during the period. State of Michigan Retirement System boosted its stake in Roivant Sciences by 1.2% during the 3rd quarter. State of Michigan Retirement System now owns 102,400 shares of the company’s stock worth $1,549,000 after acquiring an additional 1,200 shares during the last quarter. Bessemer Group Inc. grew its holdings in Roivant Sciences by 41.5% during the third quarter. Bessemer Group Inc. now owns 1,852 shares of the company’s stock valued at $28,000 after purchasing an additional 543 shares during the period. Hantz Financial Services Inc. increased its stake in Roivant Sciences by 23.2% in the third quarter. Hantz Financial Services Inc. now owns 17,629 shares of the company’s stock valued at $267,000 after purchasing an additional 3,315 shares in the last quarter. Finally, Allianz Asset Management GmbH acquired a new stake in Roivant Sciences in the third quarter worth $261,000. Institutional investors and hedge funds own 64.76% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the stock. Leerink Partners boosted their price target on shares of Roivant Sciences from $29.00 to $32.00 and gave the company an “outperform” rating in a report on Monday, December 15th. Wall Street Zen raised Roivant Sciences from a “strong sell” rating to a “hold” rating in a research note on Sunday, November 16th. TD Cowen restated a “buy” rating on shares of Roivant Sciences in a report on Saturday. HC Wainwright lifted their price objective on Roivant Sciences from $26.00 to $33.00 and gave the company a “buy” rating in a report on Tuesday. Finally, Guggenheim boosted their price objective on Roivant Sciences from $28.00 to $30.00 and gave the company a “buy” rating in a research report on Monday. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Roivant Sciences has an average rating of “Moderate Buy” and an average target price of $28.69.

Insider Buying and Selling at Roivant Sciences

In other Roivant Sciences news, major shareholder Vivek Ramaswamy sold 1,975,858 shares of the company’s stock in a transaction that occurred on Friday, December 12th. The stock was sold at an average price of $21.96, for a total transaction of $43,389,841.68. Following the completion of the transaction, the insider owned 36,350,621 shares of the company’s stock, valued at $798,259,637.16. This represents a 5.16% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Matthew Gline sold 1,740,000 shares of Roivant Sciences stock in a transaction that occurred on Monday, December 15th. The shares were sold at an average price of $21.68, for a total transaction of $37,723,200.00. Following the completion of the sale, the chief executive officer owned 17,290,820 shares in the company, valued at $374,864,977.60. This trade represents a 9.14% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 12,132,392 shares of company stock valued at $262,349,645 in the last 90 days. 10.80% of the stock is currently owned by corporate insiders.

Roivant Sciences Trading Down 1.2%

ROIV stock opened at $27.35 on Wednesday. The stock has a 50-day moving average price of $22.36 and a two-hundred day moving average price of $18.08. Roivant Sciences Ltd. has a 1 year low of $8.73 and a 1 year high of $27.94. The stock has a market cap of $19.02 billion, a PE ratio of -23.38 and a beta of 1.22.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.